according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/06/2024
11.0	07/06/2024	24515-00023	Date of first issue: 10/21/2014

SECTION 1. IDENTIFICATION

Product name	:	Sitagliptin / Simvastatin Formulation			
Manufacturer or supplier's	deta	ails			
Company name of supplier Address		Merck & Co., Inc 126 E. Lincoln Avenue Rahway, New Jersey U.S.A. 07065			
Telephone Emergency telephone E-mail address	:	908-740-4000 1-908-423-6000 EHSDATASTEWARD@merck.com			
Recommended use of the chemical and restrictions on use					
Recommended use		Pharmaceutical			

Restrictions on use	: Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR
1910.1200)

Combustible dust

Eye irritation	:	Category 2A
Skin sensitization	:	Category 1
Carcinogenicity (Inhalation)	:	Category 2
Specific target organ toxicity - repeated exposure	:	Category 1 (Liver, muscle, optic nerve, Eye)
GHS label elements Hazard pictograms	:	
Signal Word	:	Danger
Hazard Statements	:	If small particles are generated during further pro

Hazard Statements	:	If small particles are generated during further processing, han- dling or by other means, may form combustible dust concentra- tions in air. H317 May cause an allergic skin reaction. H319 Causes serious eye irritation. H351 Suspected of causing cancer if inhaled. H372 Causes damage to organs (Liver, muscle, optic nerve, Eye) through prolonged or repeated exposure.
Precautionary Statements	:	Prevention:

P201 Obtain special instructions before use.

according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

Version 11.0	Revision Date: 07/06/2024	SDS Number: 24515-00023	Date of last issue: 04/06/2024 Date of first issue: 10/21/2014
		and understoo P260 Do not b P264 Wash sk P270 Do not e P272 Contami the workplace	preathe dust. kin thoroughly after handling. eat, drink or smoke when using this product. Inated work clothing must not be allowed out of otective gloves, protective clothing, eye protectior
		P305 + P351 - for several mir to do. Continu P308 + P313 P333 + P313 tion. P337 + P313	F ON SKIN: Wash with plenty of soap and water. + P338 IF IN EYES: Rinse cautiously with water nutes. Remove contact lenses, if present and eas e rinsing. F exposed or concerned: Get medical attention. If skin irritation or rash occurs: Get medical atten- f eye irritation persists: Get medical attention. ontaminated clothing before reuse.
		Storage: P405 Store loo	cked up.
		Disposal:	of contents and container to an approved waste
••	r hazards known.		
SECTION	3. COMPOSITION/II	NFORMATION ON INC	GREDIENTS
	tance / Mixture ponents	: Mixture	

Chemical name	CAS-No.	Concentration (% w/w)
Sitagliptin	654671-77-9	>= 10 - < 20
Cellulose	9004-34-6	>= 5 - < 10
Simvastatin	79902-63-9	>= 1 - < 5
Starch	9005-25-8	>= 1 - < 5
Ascorbic acid	50-81-7	>= 1 - < 5
Titanium dioxide	13463-67-7	>= 0.1 - < 1

Actual concentration is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice	 In the case of accident or if you feel unwell, seek medical advice immediately.
	When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	: If inhaled, remove to fresh air. Get medical attention.

according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

Version 11.0	Revision Date: 07/06/2024		DS Number: 1515-00023	Date of last issue: 04/06/2024 Date of first issue: 10/21/2014
In case of skin contact		:	Remove contamin Get medical atter Wash clothing be	
In case of eye contact		:	In case of contact for at least 15 min	t, immediately flush eyes with plenty of water nutes. ove contact lens, if worn.
lf sw	allowed	:	If swallowed, DO Get medical atter	NOT induce vomiting. ition if symptoms occur. oughly with water.
	t important symptoms effects, both acute and yed	:	Causes serious e Suspected of cau	ergic skin reaction. ye irritation. sing cancer if inhaled. to organs through prolonged or repeated
	ection of first-aiders es to physician	:	First Aid respond and use the recor when the potentia	ers should pay attention to self-protection, mmended personal protective equipment al for exposure exists (see section 8). cally and supportively.
NOLE	is to physiciall	·	near symptomati	

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion prod- ucts	:	Carbon oxides Metal oxides Oxides of phosphorus
Specific extinguishing meth- ods	:	Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- :	Use personal protective equipment.
tive equipment and emer-	Follow safe handling advice (see section 7) and personal
gency procedures	protective equipment recommendations (see section 8).

according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

Version 11.0	Revision Date: 07/06/2024		0S Number: 515-00023	Date of last issue: 04/06/2024 Date of first issue: 10/21/2014	
Environmental precautions		:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.		
Methods and materials for containment and cleaning up		:	container for disp Avoid dispersal of with compressed Dust deposits sho surfaces, as these released into the Local or national disposal of this m employed in the of determine which n Sections 13 and 1	f dust in the air (i.e., clearing dust surfaces	

SECTION 7. HANDLING AND STORAGE

Technical measures	Static electricity may accumulate and ignite suspended dust causing an explosion.
	Provide adequate precautions, such as electrical grounding
	and bonding, or inert atmospheres.
Local/Total ventilation	Use only with adequate ventilation.
Advice on safe handling	Do not get on skin or clothing.
_	Do not breathe dust.
	Do not swallow.
	Do not get in eyes.
	Wash skin thoroughly after handling.
	Handle in accordance with good industrial hygiene and safety
	practice, based on the results of the workplace exposure
	assessment
	Minimize dust generation and accumulation.
	Keep container closed when not in use.
	Keep away from heat and sources of ignition.
	Take precautionary measures against static discharges.
	Do not eat, drink or smoke when using this product.
	Take care to prevent spills, waste and minimize release to the
	environment.
Conditions for safe storage	Keep in properly labeled containers.
	Store in accordance with the particular national regulations.
Materials to avoid	Do not store with the following product types:
	Strong oxidizing agents
	Self-reactive substances and mixtures
	Organic peroxides
	Explosives
	Gases

according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/06/2024
11.0	07/06/2024	24515-00023	Date of first issue: 10/21/2014

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace co	ontrol paramete	rs			
inert or nuisance dust	50 Million particles per cubic foot Value type (Form of exposure): TWA (total dust) Basis: OSHA Z-3				
	15 mg/m³ Value type (Form of exposure): TWA (total dust) Basis: OSHA Z-3				
	5 mg/m³ Value type (Fo Basis: OSHA 2		: TWA (respirable fra	ction)	
			oot : TWA (respirable fra	ction)	
Dust, nuisance dust and par- ticulates	10 mg/m³ Value type (Fo Basis: CAL PE		: PEL (Total dust)		
	5 mg/m³ Value type (Form of exposure): PEL (respirable dust fraction) Basis: CAL PEL				
Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis	
Sitagliptin	654671-77-9	TWA	0.5 mg/m3 (OEB 2)	Internal	
Cellulose	9004-34-6	TWA	10 mg/m ³	ACGIH	
		TWA (Res- pirable)	5 mg/m ³	NIOSH REL	
		TWA (total)	10 mg/m ³	NIOSH REL	
		TWA (total dust)	15 mg/m ³	OSHA Z-1	
		TWA (respir- able fraction)	5 mg/m ³	OSHA Z-1	
Simvastatin	79902-63-9	TWA	25 µg/m3 (OEB 3)	Internal	
	Further information	ation: DSEN			
		Wipe limit	250 µg/100 cm ²	Internal	
Starch	9005-25-8	TWA	10 mg/m ³	ACGIH	
		TWA (Res- pirable)	5 mg/m³	NIOSH REL	
		TWA (total)	10 mg/m ³	NIOSH REL	
		TWA (total dust)	15 mg/m ³	OSHA Z-1	
		TWA (respir- able fraction)	5 mg/m³	OSHA Z-1	
Ascorbic acid	50-81-7	TWA	5000 µg/m3 (OEB	Internal	





Version Revision Date: 11.0 07/06/2024			DS Number: I515-00023	Date of last issue: 04/06/2024 Date of first issue: 10/21/2014		
					1)	
Titani	ium dioxide		13463-67-7	TWA (total dust)	15 mg/m³	OSHA Z-1
Engi	neering measures	:	design and op protect produc Containment t are required to	berated in accord cts, workers, and technologies sui o control at sour d to uncontrolled devices).	d be implemented dance with GMP d the environmen table for controllin ce and to preven areas (e.g., open	principles to t. ng compounds t migration of
Perse	onal protective equip	ment	:			
Respiratory protection : Gener mainta conce unkno Follow use Ni by air hazard supplie releas circum			maintain vapo concentration unknown, app Follow OSHA use NIOSH/M by air purifying hazardous ch supplied respi release, expo	Seneral and local exhaust ventilation is recommended to naintain vapor exposures below recommended limits. Where oncentrations are above recommended limits or are nknown, appropriate respiratory protection should be worn. follow OSHA respirator regulations (29 CFR 1910.134) and se NIOSH/MSHA approved respirators. Protection provided y air purifying respirators against exposure to any azardous chemical is limited. Use a positive pressure air upplied respirator if there is any potential for uncontrolled elease, exposure levels are unknown, or any other ircumstance where air purifying respirators may not provide		
Hand	protection					
M	aterial	:	Chemical-resi	stant gloves		
	emarks protection	:	 Consider double gloving. Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or 			
Skin	and body protection	:	 aerosols. Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentia contaminated clothing. 			
Hygie	ene measures	:	If exposure to eye flushing s working place When using d Contaminated workplace. Wash contam The effective engineering c appropriate de	chemical is like ystems and safe o not eat, drink o l work clothing s inated clothing b operation of a fa ontrols, proper p egowning and do	hould not be allo	e to the wed out of the ide review of e equipment, rocedures,

according to the OSHA Hazard Communication Standard



Versior 11.0	n Revision Date: 07/06/2024		S Number: 515-00023	Date of last issue: 04/06/2024 Date of first issue: 10/21/2014	
			use of administrat	ive controls.	
SECTI	ON 9. PHYSICAL AND CH	EMIC	CAL PROPERTIES	3	
Ap	opearance	:	powder		
Co	blor	:	pink		
O	dor	:	No data available	9	
O	dor Threshold	:	No data available	9	
p⊦	1	:	No data available	9	
Me	elting point/freezing point	:	No data available	9	
	tial boiling point and boiling nge	:	No data available	9	
Fla	ash point	:	Not applicable		
E٧	vaporation rate	:	Not applicable		
Fla	ammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.		
Fla	ammability (liquids)	:	No data available	9	
	oper explosion limit / Upper mmability limit	:	No data available		
	wer explosion limit / Lower mmability limit	:	No data available		
Va	apor pressure	:	Not applicable		
Re	elative vapor density	:	Not applicable		
Re	elative density	:	No data available	9	
De	ensity	:	No data available	9	
So	blubility(ies) Water solubility	:	No data available		
	artition coefficient: n- tanol/water	:	Not applicable		
	itoignition temperature	:	No data available	9	
De	ecomposition temperature	:	No data available	9	
Vi	scosity Viscosity, kinematic	:	Not applicable		

according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

Version 11.0	Revision Date: 07/06/2024		Number: 5-00023	Date of last issue: 04/06/2024 Date of first issue: 10/21/2014
Explos	sive properties	: 1	Not explosive	
Oxidiz	ing properties	: -	The substance o	r mixture is not classified as oxidizing.
Molec	ular weight	: 1	No data available	9
Particl Particl	le characteristics le size	: 1	No data available	9

SECTION 10. STABILITY AND REACTIVITY

Reactivity Chemical stability Possibility of hazardous reac- tions	 Not classified as a reactivity hazard. Stable under normal conditions. May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	: Heat, flames and sparks. Avoid dust formation.
Incompatible materials	: Oxidizing agents
Hazardous decomposition products	: No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Components:

Sitagliptin:

Acute oral toxicity	:	LD50 (Rat): > 3,000 mg/kg
		LD50 (Mouse): 3,000 mg/kg
Cellulose:		
Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 5.8 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute dermal toxicity	:	LD50 (Rabbit): > 2,000 mg/kg

according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

Version 11.0	Revision Date: 07/06/2024	SDS Numbe 24515-00023		
Simv	astatin:			
	e oral toxicity	: LD50 (Ra	at): 5,000 mg/kg	
			ouse): 3,800 mg/kg	
			ouse). 3,000 mg/kg	
Starc	:h:			
Acute	e oral toxicity	: LD50 (Ra	at): > 5,000 mg/kg	
Acute	e dermal toxicity	: LD50 (Ra	abbit): > 2,000 mg/kg	
Asco	orbic acid:			
Acute	e oral toxicity	: LD50 (Ra	at): 11,900 mg/kg	
Titan	ium dioxide:			
Acute	e oral toxicity	: LD50 (Ra	at): > 5,000 mg/kg	
Acute	e inhalation toxicity	Exposure Test atm Assessm	LC50 (Rat): > 6.82 mg/l Exposure time: 4 h Test atmosphere: dust/mist Assessment: The substance or mixture has no acute inhala- tion toxicity	
-	corrosion/irritation lassified based on ava	ailable informatio	n.	
Com	ponents:			
Sitad	liptin:			
Spec		: Rabbit		
Meth		: Draize To		
Resu	It	: No skin i	ritation	
Simv	astatin:			
Spec	ies	: Rabbit		
Rema	arks	: Moderate	e skin irritation	
Asco	orbic acid:			
Spec		: Rabbit		
Metho		: OECD T	est Guideline 404	
Resu	lt	: No skin i	rritation	
Titan	ium dioxide:			
Spec		: Rabbit		
Resu		: No skin i	rritation	

Serious eye damage/eye irritation

Causes serious eye irritation.

according to the OSHA Hazard Communication Standard



Version 11.0	Revision Date: 07/06/2024	SDS Number: 24515-00023	Date of last issue: 04/06/2024 Date of first issue: 10/21/2014
Com	ponents:		
Sitag	liptin:		
Spec		: Rabbit	
Resu		: Irritating to e	/es.
Metho	od	: Draize Test	
Simv	astatin:		
Spec		: Rabbit	
Rema	arks	: slight irritatio	1
Starc	:h:		
Spec	ies	: Rabbit	
Resu	lt	: No eye irritat	on
Asco	rbic acid:		
Spec	ies	: Rabbit	
Resu		: No eye irritat	
Metho	od	: OECD Test (Guideline 405
Titan	ium dioxide:		
Spec		: Rabbit	
Resu	lt	: No eye irritat	on
Resp	iratory or skin sens	itization	
Skin	sensitization		
May o	cause an allergic skin	reaction.	
Resp	iratory sensitization	1	
-	lassified based on av		
Com	ponents:		
Sitag	liptin:		
Test			node assay (LLNA)
Spec		: Mouse	
Metho Resu		: OECD Test (: Not a skin se	
Resu	it.	. NOT a SKIT SE	
	astatin:		
	ssment		evidence of skin sensitization in humans
Resu	It	: positive	
Starc			
Test	Type es of exposure	: Maximization	Test
Route	es of exposure	: Skin contact	
Spec Resu	ies	: Guinea pig : negative	
IIVESU		. negative	
		10 /	24

according to the OSHA Hazard Communication Standard



ersion .0	Revision Date: 07/06/2024	SDS Number: 24515-00023	Date of last issue: 04/06/2024 Date of first issue: 10/21/2014
Asco	rbic acid:		
Test		: Maurer optimis	sation test
	es of exposure	: Skin contact	
Speci		: Guinea pig	
Resu	lt	: negative	
Titan	ium dioxide:		
Test			ode assay (LLNA)
	es of exposure	: Skin contact	
Speci		: Mouse	
Resu	lt	: negative	
	cell mutagenicity		
	lassified based on av ponents:	ailable information.	
	liptin:		
Geno	toxicity in vitro	: Test Type: Am	es test
		Result: negativ	
		Test Type: Ch	romosome aberration test in vitro
		Test system: C Result: negativ	Chinese hamster ovary cells /e
Geno	toxicity in vivo	: Test Type: Mic	ronucleus test
Cono		Species: Mous	
		Application Ro	
		Result: negativ	
Cellu	lose:		
Geno	toxicity in vitro	: Test Type: Bao Result: negativ	cterial reverse mutation assay (AMES) /e
		Test Type: In v Result: negativ	vitro mammalian cell gene mutation test ve
Geno	toxicity in vivo	: Test Type: Ma cytogenetic as Species: Mous Application Ro Result: negativ	e ute: Ingestion
11			
Simv	astatin:		

according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

ersion 1.0	Revision Date: 07/06/2024	SDS Number:Date of last issue: 04/06/202424515-00023Date of first issue: 10/21/2014	
II		Result: negative	
		Test Type: Alkaline elution assay Result: negative	
		Test Type: Chromosomal aberration Result: negative	
		Test Type: In vitro mammalian cell gene mutation test Result: negative	
Geno	toxicity in vivo	: Test Type: Micronucleus test Species: Mouse Application Route: Oral Result: negative	
	cell mutagenicity -	: Weight of evidence does not support classification as a cell mutagen.	germ
Starc	h:		
Geno	toxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative	
Asco	rbic acid:		
Geno	toxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative	
		Test Type: In vitro mammalian cell gene mutation test Result: negative	
		Test Type: Chromosome aberration test in vitro Result: negative	
Geno	toxicity in vivo	: Test Type: Mammalian erythrocyte micronucleus test (in cytogenetic assay) Species: Mouse Application Route: Ingestion Result: negative	ı vivo
Titani	ium dioxide:		
Geno	toxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative	
Geno	toxicity in vivo	: Test Type: In vivo micronucleus test Species: Mouse Result: negative	

Carcinogenicity

Suspected of causing cancer if inhaled.

according to the OSHA Hazard Communication Standard



Version 11.0	Revision Date: 07/06/2024	SDS Number: 24515-00023	Date of last issue: 04/06/2024 Date of first issue: 10/21/2014
Comp	oonents:		
Sitag	liptin:		
Speci	es	: Mouse	
Applic	cation Route sure time	: Oral	
Resul		: 2 Years : negative	
Speci	es	: Rat	
Applic	ation Route	: oral (drinking v	vater)
	sure time	: 2 Years	
Resul Targe	t Organs	: positive : Liver	
Rema			city observed in testing
Carcir ment	nogenicity - Assess-	: Weight of evide cinogen	ence does not support classification as a car-
Cellul	lose:		
Speci		: Rat	
	cation Route	: Ingestion	
Resul	sure time t	: 72 weeks : negative	
i tooui		. nogative	
	astatin:		
Speci		: Mouse	
	cation Route sure time	: Oral : < 92 weeks	
	t Organs	: Harderian glan	nd
	r Type	: Liver, Lungs	
Rema		: The significant	ce of these findings for humans is not certain.
Speci	es	: Rat	
Applic	cation Route	: Oral	
Expos	sure time r Type	: 2 Years : Liver, Thyroid	
Rema			ce of these findings for humans is not certain.
Δερο	rbic acid:		
Speci		: Mouse	
	cation Route	: Ingestion	
	sure time	: 2 Years	
Resul	t	: negative	
Titani	ium dioxide:		
Speci		: Rat	
	cation Route	: inhalation (dus	t/mist/fume)
Expos	sure time	: 2 Years : OECD Test Gu	udeline 453
Resul		: positive	
Rema	ırks		m or mode of action may not be relevant in hu-

according to the OSHA Hazard Communication Standard



Version 11.0	Revision Date: 07/06/2024	SDS Number:Date of last issue: 04/06/202424515-00023Date of first issue: 10/21/2014
II		mans.
Carcin ment	ogenicity - Assess-	: Limited evidence of carcinogenicity in inhalation studies with animals.
IARC	Group 2B: P Titanium dio	ossibly carcinogenic to humans xide 13463-67-7
II OSHA		ent of this product present at levels greater than or equal to 0.1% is is is of regulated carcinogens.
NTP		t of this product present at levels greater than or equal to 0.1% is a known or anticipated carcinogen by NTP.
-	ductive toxicity assified based on avai	able information.
<u>Comp</u>	onents:	
Sitagli	ptin:	
Effects	s on fertility	 Test Type: Fertility/early embryonic development Species: Rat Application Route: Oral Fertility: NOAEL Parent: 1,000 mg/kg body weight Result: Animal testing did not show any effects on fertility.
Effects	s on fetal development	: Test Type: Embryo-fetal development Species: Rat Application Route: Oral Teratogenicity: LOAEL: 250 mg/kg body weight Result: Embryotoxic effects and adverse effects on the offspring were detected., No teratogenic effects.
		Test Type: Embryo-fetal development Species: Rabbit Teratogenicity: NOAEL: 125 mg/kg body weight Result: No teratogenic effects.
Cellul	ose:	
	s on fertility	: Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative
Effects	on fetal development	: Test Type: Fertility/early embryonic development Species: Rat Application Route: Ingestion Result: negative
II Simva	statin:	
	s on fertility	: Test Type: Fertility Species: Rat, male

according to the OSHA Hazard Communication Standard



Version 11.0	Revision Date: 07/06/2024		OS Number: 515-00023	Date of last issue: 04/06/2024 Date of first issue: 10/21/2014
			Application Route Fertility: LOAEL:	e: Oral 25 mg/kg body weight
Effec	Effects on fetal development :		Species: Rat Application Route Embryo-fetal toxi	yo-fetal development e: Oral city.: NOAEL: 25 mg/kg body weight genic effects., No adverse effects.
			Species: Rabbit Application Route Embryo-fetal toxi	yo-fetal development e: Oral city.: NOAEL: 10 mg/kg body weight genic effects., No adverse effects.
			Species: Rat Application Route Embryo-fetal toxi Result: Teratoget	city.: LOAEL: 60 mg/kg body weight
Asco	rbic acid:			
	ts on fetal development	:	Test Type: Embry Species: Rat Application Route Result: negative	yo-fetal development e: Ingestion
	F-single exposure lassified based on availa	able	information.	
	F-repeated exposure es damage to organs (L	iver	muscle, optic ner	ve, Eye) through prolonged or repeated expo-
Com	oonents:			
Targe	astatin: et Organs ssment	:	Liver, muscle, op Causes damage exposure.	tic nerve, Eye to organs through prolonged or repeated
Repe	ated dose toxicity			
	oonents:			
	liptin:			
Spec	es	:	Mouse 500 ma/ka	

Species	:	Mouse
NOAEL	:	500 mg/kg
LOAEL	:	1,000 mg/kg
Application Route	:	Oral
Exposure time	:	> 2 y
Target Organs	:	Kidney

according to the OSHA Hazard Communication Standard



Version 11.0	Revision Date: 07/06/2024	SDS Number: 24515-00023	Date of last issue: 04/06/2024 Date of first issue: 10/21/2014
Expos	EL	: Rat : 500 mg/kg : 1,000 mg/kg : Oral : 14 Weeks : Liver, Kidney	, Heart, Teeth
Expos	EL EL cation Route sure time t Organs toms	: Dog : 10 mg/kg : 50 mg/kg : Oral : 53 Weeks : Central nervo : Loss of balan : The mechani humans.	
Expos	EL EL cation Route sure time t Organs toms	: Loss of balan	cle, Central nervous system ice sm or mode of action may not be relevant in
	EL cation Route sure time	: Monkey : 100 mg/kg : Oral : 14 Weeks : No significan	t adverse effects were reported
Cellul Speci NOAE Applic Expos	es	: Rat : >= 9,000 mg/ : Ingestion : 90 Days	′kg
Specie NOAE LOAE Applic Expos	EL	: Rat : 5 mg/kg : 30 mg/kg : Oral : 14 - 104 Wee : Liver, Testis,	eks Musculo-skeletal system, Eye
		: Dog : 10 mg/kg : Oral : 14 - 104 Wee	eks

according to the OSHA Hazard Communication Standard



Version 11.0	Revision Date: 07/06/2024		DS Number: 515-00023	Date of last issue: 04/06/2024 Date of first issue: 10/21/2014
Target	t Organs	:	Liver, Testis, Eye	
	L	:	Rabbit 30 mg/kg 50 mg/kg Oral Liver, Kidney	
Starch				
	L ation Route ure time	:	Rat >= 2,000 mg/kg Skin contact 28 Days OECD Test Guide	eline 410
Ascor	bic acid:			
		:	Rat, male >= 8,100 mg/kg Ingestion 13 Weeks	
Titani	um dioxide:			
		:	Rat 24,000 mg/kg Ingestion 28 Days	
		:	Rat 10 mg/m³ inhalation (dust/m 2 y	ist/fume)
Aspira	ation toxicity			
•	assified based on avai	lable	information.	
Exper	ience with human ex	posi	ure	
<u>Comp</u>	onents:			
Sitagl Inhala		:		respiratory tract infection, pharyngitis,
Ingest	ion	:		r respiratory tract infection, nasopharyngitis, ea, Abdominal pain, Diarrhea
	istatin:			
Skin c Ingest		:	Target Organs: Li Symptoms: upper dominal pain, con	oduce an allergic reaction. ver respiratory tract infection, Headache, Ab- stipation, Nausea usculo-skeletal system

according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

VersionRevision Date:SDS Number:Date of last issue: 04/06/202411.007/06/202424515-00023Date of first issue: 10/21/2014

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Sitagliptin:		
Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 60 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 39 mg/l Exposure time: 96 h Method: OECD Test Guideline 201
		NOEC (Pseudokirchneriella subcapitata (green algae)): 2.2 mg/l Exposure time: 96 h Method: OECD Test Guideline 201
Toxicity to fish (Chronic tox- icity)	:	NOEC (Pimephales promelas (fathead minnow)): 9.2 mg/l Exposure time: 33 d Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chron-ic toxicity)	:	NOEC (Daphnia magna (Water flea)): 9.8 mg/l Exposure time: 21 d Method: OECD Test Guideline 211
Toxicity to microorganisms	:	EC50: > 150 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209
		NOEC: 150 mg/l Exposure time: 3 h Test Type: Respiration inhibition
Cellulose:		
Toxicity to fish	:	LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l Exposure time: 48 h Remarks: Based on data from similar materials
Simvastatin:		
Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): 2.91 mg/l Exposure time: 96 h Method: OECD Test Guideline 203

according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

ersion .0	Revision Date: 07/06/2024		0S Number: 515-00023	Date of last issue: 04/06/2024 Date of first issue: 10/21/2014
	ity to daphnia and other ic invertebrates	:	EC50 (Daphnia m Exposure time: 48 Method: OECD Te	
Toxici plants	ity to algae/aquatic	:	EC50 (Pseudokiro mg/l Exposure time: 96	chneriella subcapitata (green algae)): > 25 S h
			NOEC (Pseudokir mg/l Exposure time: 96	rchneriella subcapitata (green algae)): 25 S h
Toxici	ty to microorganisms	:	EC50: > 30 mg/l Exposure time: 3 Test Type: Respir Method: OECD Te	ation inhibition
			NOEC: 21 mg/l Exposure time: 3 Test Type: Respir Method: OECD Te	ation inhibition
Asco	rbic acid:			
	ity to fish	:	LC50 (Oncorhync Exposure time: 96 Method: OECD Te	
Toxici	ty to microorganisms	:	EC50: 140 mg/l Exposure time: 16 Method: DIN 38 4	
Titani	ium dioxide:			
	ity to fish	:	LC50 (Oncorhync Exposure time: 96 Method: OECD Te	
	ty to daphnia and other ic invertebrates	:	EC50 (Daphnia m Exposure time: 48	agna (Water flea)): > 100 mg/l 3 h
Toxici plants	ty to algae/aquatic	:	EC50 (Skeletoner Exposure time: 72	ma costatum (marine diatom)): > 10,000 mg/l 2 h
Toxici	ty to microorganisms	:	EC50: > 1,000 mg Exposure time: 3 Method: OECD Te	h
Persi	stence and degradabil	ity		
<u>Com</u> r	oonents:			
Sitag				
-	aradability		Recult: not rapidly	, degradable

Biodegradability

: Result: not rapidly degradable

according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

/ersion 11.0	Revision Date: 07/06/2024		DS Number: 515-00023	Date of last issue: 04/06/2024 Date of first issue: 10/21/2014
			Biodegradation: Exposure time: 2 Method: OECD T	
Stabi	lity in water	:		(401 d) Test Guideline 111
Cellu	lose:			
Biode	egradability	:	Result: Readily b	iodegradable.
Simv	astatin:			
Biode	egradability	:	Result: rapidly de	egradable
Stabi	lity in water	:	Hydrolysis: 50 %	(3.2 d)
Asco	rbic acid:			
	gradability	:	Result: Readily b Biodegradation: Exposure time: 5 Method: OECD T	97 %
Bioa	ccumulative potential			
Com	ponents:			
-	liptin:			
Partit	ion coefficient: n- ol/water	:	log Pow: -0.03	
Simv	astatin:			
	ion coefficient: n- ol/water	:	log Pow: > 4.07	
Asco	rbic acid:			
	ion coefficient: n- ol/water	:	log Pow: -1.85	
Mobi	lity in soil			
Com	ponents:			
Sitag	liptin:			
Distri		:	log Koc: 4.37	
Othe	r adverse effects			
No da	ata available			

Disposal methods

Waste from residues

: Dispose of in accordance with local regulations.

according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/06/2024		
11.0	07/06/2024	24515-00023	Date of first issue: 10/21/2014		
Conta	aminated packaging	: Empty contain handling site for	e of waste into sewer. ers should be taken to an approved waste or recycling or disposal. e specified: Dispose of as unused product.		

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code Not applicable for product as supplied.

Domestic regulation

49 CFR Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards	Combustible dust Respiratory or skin sensitization Carcinogenicity Specific target organ toxicity (single or repeated exposure) Serious eye damage or eye irritation
SARA 313 :	This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know

D-Glucose, 4-O-β-D-galactopyranosyl-, monohydrate	64044-51-5
Calcium hydrogenorthophosphate	7757-93-9






Sitagliptin / Simvastatin Formulation

Version 11.0	Revision Date: 07/06/2024	SDS Number: 24515-00023	Date of last issue: 04/06/2024 Date of first issue: 10/21/2014	
	Sitagliptin Cellulose Starch Simvastatin		654671-77-9 9004-34-6 9005-25-8 79902-63-9	
California Prop. 65 WARNING: This product can expose you to chemicals including Titanium dioxide, which is/are known to the State of California to cause cancer. For more information go to www.P65Warnings.ca.gov.				
Califo	California Permissible Exposure Limits for Chemical Contaminants			
	Cellulose Starch		9004-34-6 9005-25-8	
The ingredients of this product are reported in the following inventories:				
AICS		: not determined		
DSL		: not determined		
IECS	С	: not determined		

SECTION 16. OTHER INFORMATION

Further information

NFPA 704:



HMIS® IV:



HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH CAL PEL	USA. ACGIH Threshold Limit Values (TLV) California permissible exposure limits for chemical contami- nants (Title 8, Article 107)
NIOSH REL OSHA Z-1	USA. NIOSH Recommended Exposure Limits USA. Occupational Exposure Limits (OSHA) - Table Z-1 Lim- its for Air Contaminants



Sitagliptin / Simvastatin Formulation

Version 11.0	Revision Date: 07/06/2024	SDS Number: 24515-00023	Date of last issue: 04/06/2024 Date of first issue: 10/21/2014	
OSHA	x Z-3	: USA. Occupa eral Dusts	ational Exposure Limits (OSHA) - Table Z-3 Min-	
ACGI	H / TWA	: 8-hour, time-	weighted average	
CAL F	PEL / PEL	: Permissible e	exposure limit	
NIOSI	HREL/TWA		ed average concentration for up to a 10-hour ng a 40-hour workweek	
	x Z-1 / TWA x Z-3 / TWA		8-hour time weighted average8-hour time weighted average	

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC -International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen- cy, http://echa.europa.eu/

Revision Date : 07/06/2024

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a

according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/06/2024
11.0	07/06/2024	24515-00023	Date of first issue: 10/21/2014

guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8